which glp-1 has least gi side effects Comparing Ozempic, Wegovy and Other Drugs Which GLP-1 Has Less Side

Lillys small-molecule GLP-1 agonist orforglipron (brand Foundayo) also gained FDA approval in April 2026 for weight loss and is expected to launch in 2027, marking a breakthrough as the first non-peptidic GLP-1 pill ( [35] )

[1] [6] The proposed mechanisms linking these therapies to gallbladder complications include altered gallbladder motility and bile composition changes

The presence of non-responders to GLP-1R therapy continues to complicate treatment outcomes, underscoring the need for a deeper understanding of individual variability in response [117,118]

Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: a meta-analysis and meta-regression

The drugs have shown positive effects on liver function tests and possible advantages in non-alcoholic fatty liver disease (Liao et al

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8)